Erythromycin
Severe
Textbook
Increased risk of Q-T prolongation and arrhythmias, including torsades de pointes.
Caution/monitor for Q-T prolongation; consider alternatives if necessary.
Source: KDT 7e · p667
Drug reference
mosapride
Prokinetic, 5-HT4 agonist, weak 5-HT3 antagonist
Prokinetic, 5-HT4 agonist, weak 5-HT3 antagonist
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
1 major
SEVERE in our sources
PREGNANCY
—
not curated
Top interactions
- ErythromycinSevereTextbookKDT 7e · p667
Mechanism
Gastrokinetic and LES tonic action due to 5-HT4 agonistic (major) and 5-HT3 antagonistic (minor) action in the myenteric plexus.
Indications
nonulcer dyspepsiadiabetic gastroparesisgastroesophageal reflux disease (GERD, as adjuvant to H2 blockers/PPIs)some cases of chronic constipation
Dosing
- Adult
- 5 mg TDS
- Geriatric
- 2.5 mg TDS
Contraindications
- concomitant use with CYP3A4 inhibitors (erythromycin, other CYP3A4 inhibitors)
Side effects
Common
diarrhoeaabdominal painheadachedizzinessinsomnia
Serious
- Q-T prolongation
- arrhythmias (including torsades de pointes)
Drug interactions
Related guidelines
Ask House about mosapride
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: KD Tripathi 7e·Verified: 2026-05-10 · House clinical team